BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 12448566)

  • 21. Treatment of tumor lysis syndrome with the highest known uric acid level.
    Ozkan G; Ulusoy S; Sönmez M; Kaynar K; Karagülle M
    Ren Fail; 2010; 32(7):895-8. PubMed ID: 20662707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor lysis syndrome: pathogenesis and management.
    Jones DP; Mahmoud H; Chesney RW
    Pediatr Nephrol; 1995 Apr; 9(2):206-12. PubMed ID: 7794722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials.
    Seidemann K; Meyer U; Jansen P; Yakisan E; Rieske K; Führer M; Kremens B; Schrappe M; Reiter A
    Klin Padiatr; 1998; 210(4):279-84. PubMed ID: 9743966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour lysis syndrome in children: experience of last decade.
    Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
    Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
    Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
    Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hyperuricemia and the kidney].
    Ichida K; Hikita M; Hosoya T
    Nihon Rinsho; 1996 Dec; 54(12):3277-82. PubMed ID: 8976105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acute renal failure in paediatric oncological disease].
    Stefanowicz J; Maciejka-Kapuścińska L; Rückemann-Dziurdzińska K; Drozyńska-Duklas M; Zurowska A; Balcerska A
    Med Wieku Rozwoj; 2007; 11(3 Pt 2):337-41. PubMed ID: 18663277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour lysis syndrome: implications for cancer therapy.
    Mika D; Ahmad S; Guruvayoorappan C
    Asian Pac J Cancer Prev; 2012; 13(8):3555-60. PubMed ID: 23098434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor lysis syndrome.
    Rajendran A; Bansal D; Marwaha RK; Singhi SC
    Indian J Pediatr; 2013 Jan; 80(1):50-4. PubMed ID: 22752730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onco-nephrology: tumor lysis syndrome.
    Wilson FP; Berns JS
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1730-9. PubMed ID: 22879434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J
    Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-asparginase administration reduces white blood cell count and prevents tumor lysis syndrome in children with hyperleukocytic acute lymphoblastic leukemia.
    Sondhi V; Sharma A; Taneja M; Arora B; Banavali SD
    Acta Haematol; 2015; 133(1):6-9. PubMed ID: 24968963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The management of tumor lysis syndrome.
    Rampello E; Fricia T; Malaguarnera M
    Nat Clin Pract Oncol; 2006 Aug; 3(8):438-47. PubMed ID: 16894389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
    Mughal TI; Ejaz AA; Foringer JR; Coiffier B
    Cancer Treat Rev; 2010 Apr; 36(2):164-76. PubMed ID: 20031331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia.
    Xue Y; Chen J; Gao S; Zhai X; Wang N; Gao J; Lv Y; Yin M; Zhuang Y; Zhang H; Zhu X; Wu X; Li CK; Hu S; Liang C; Jin R; Jiang H; Yang M; Sun L; Pan K; Cai J; Tang J; Guan X; Fang Y
    Sci Rep; 2021 May; 11(1):9656. PubMed ID: 33958615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour lysis syndrome: new therapeutic strategies and classification.
    Cairo MS; Bishop M
    Br J Haematol; 2004 Oct; 127(1):3-11. PubMed ID: 15384972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hyperuricemia in hematological disorders].
    Iwata J
    Nihon Rinsho; 1996 Dec; 54(12):3349-53. PubMed ID: 8976118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The specific features of renal lesion in Burkitt's lymphoma].
    Lukina AE; Bariakh EA; Kravchenko SK; Biriukova LS; Gemdzhian ÉG; Magomedova AU; Kremenetskaia AM; Vorob'ev AI
    Ter Arkh; 2012; 84(7):31-4. PubMed ID: 23038969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
    Coiffier B; Altman A; Pui CH; Younes A; Cairo MS
    J Clin Oncol; 2008 Jun; 26(16):2767-78. PubMed ID: 18509186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
    Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
    Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.